Assets

TAA Antibody Library

Biocytogen's antibody discovery team has generated a library of antibodies targeting approximately 200 tumor-associated antigens (TAAs) using RenMice® platforms -RenMab™, RenLite®, and RenNano®.

  • 200+
    TAA antibody backbones
  • 20+
    BsADC Assets
related resource

on this page

  • Advantages of Collaborating with the TAA Antibody Library
  • 200+ TAA targets at all stages 400+TAA antibody discovery projects
  • Workflow for Building the TAA Antibody Library
  • Selected assets overview

Webinars

View All

    Posters

    View All
      Advantages of Collaborating with the TAA Antibody Library:
      • Fully human antibodies with low immunogenicity.
      • Great sequence and epitope diversity.
      • Great specificity, favorable affinity range and good internalization.
      • Strong species cross-reactivity to facilitate in vivo screening.
      • Favorable physiochemical properties and good developability.
      200+ TAA targets at all stages 400+TAA antibody discovery projects
      TAA-targeting antibody backbones available for flexible plug & play
      ADAM9 AFP AMHR2 B7-H3 B7-H4 CAIX CCR9
      CD105 CD142 CD155 CD22 CD30 CD7 CD70
      CDCP1 CDH11 CDH17 CDH3 CDH6 CEACAM5 CEACAM6
      Claudin 18.2 CLDN3 CLDN6 CLEC12A DDR1 DLK1 DR5
      EGFR EPCAM EPHA2 EPHB2 FAP FLT3 FOLR1
      GPC-1 GUCY2C HER2 HER3 HLA-G HPN IL3RA
      ITGB6 KIT KREMEN2 LGR5 LIV-1 LRRC15 LUNX
      LY6G6D LYPD3 MET MSLN MUC1 MUC16 MUC18
      Nectin-4 PALP PRLR PSMA PTK7 ROR1 SEZ6
      SLC34A2 SSTR2 TIM1 5T4(TPBG) TROP2 and more
      Workflow for Building the TAA Antibody Library:
      • Knock out on RenMice generates novel epitopes.
      • Streamlined large-scale, high-throughput screening accelerates discovery of 1000+ targets.
      • Integrated antibodies development capabilities: in vivo, in vitro, CMC, and etc.
      • Flexible business model.
      Selected assets overview

      To unlock more data from the TAA Antibody Library, please feel free to Contact us anytime.

      Fully-human DLL3xB7H3 bsADCs Highlights

      DLL3 expression is highly restricted to SCLC, neuroendocrine tumors, and glioblastoma with minimally or no expression in normal tissues. B7-H3 is overexpressed in several tumor types, including SCLC. Both are validated targets for SCLC.

      Indications: SCLC

      The bsADCs had a 1+1 cononical format and were conjugated to a novel TOP1 inhibitor payload with potent bystander effect and a highly hydrophilic, enzyme-cleavable linker.

      In vitro and in vivo characterization:
      • Robust affinity to human DLL3 and B7H3(~E-10).
      • Better internalization than PCs.
      • Significant anti-tumor efficacy.

      Excellent developability under stress conditions.